USP11 alleviates pathological cardiac hypertrophy via stabilizing SIRT6 Authors: Xijia Wang, Wenzhe Zong, Di Zhou, Xiaoyang Ji, Xiaoge An, Zihe Liu, Lingyao Kong, Yihuan Wang, Yudong Fang, Lu Gao, Yue Li, Zhe Zheng, Gangqiong Liu, Siyuan Fan Published: 2026 ABSTRACT AbstractBackgroundPathological cardiac hypertrophy is a key precursor to heart failure. Protein ubiquitination and deubiquitination are crucial mechanisms controlling cardiomyocyte signaling homeostasis. USP11, a ubiquitin-specific protease, has been implicated in multiple cellular regulatory processes, but its cardiac function remains unknown. Here, we investigated whether USP11 modulates cardiac hypertrophy and explored its downstream molecular mechanisms.MethodsUSP11 expression was detected in hearts from mice subjected to transverse aortic constriction (TAC) and in phenylephrine (PE)-stimulated cardiomyocytes. Cardiomyocyte-specific overexpression of USP11 was achieved using AAV9-cTnT-USP11. The effects of USP11 on cardiac remodeling and function were evaluated by echocardiography, histology, and molecular analyses. Neonatal rat ventricular cardiomyocytes (NRVMs) were used for in vitro assays. Co-immunoprecipitation (co-IP), mass spectrometry, and ubiquitination assays were performed to explore the interaction between USP11 and SIRT6 and its mechanistic consequences.ResultsUSP11 expression was markedly decreased in hypertrophic mouse hearts and PE-treated NRVMs. Cardiomyocyte-specific overexpression of USP11 significantly alleviated TAC-induced cardiac hypertrophy and fibrosis, improving left ventricular function. In NRVMs, USP11 overexpression mitigated PE-induced cardiomyocyte hypertrophy, whereas USP11 silencing aggravated hypertrophy. Mechanistically, USP11 directly bound to and stabilized SIRT6 by removing its K48-linked ubiquitin chains, thereby preventing its proteasomal degradation. USP11 attenuated the activation of the IGF2-AKT signaling pathway by stabilizing SIRT6, while the absence of USP11 had the opposite effect. Mutation of the catalytic site of USP11 abolished both its effect on SIRT6 stabilization and its ability to attenuate cardiac hypertrophy. Furthermore, reintroduction of SIRT6 rescued the pro-hypertrophic effects of USP11 deficiency.ConclusionsUSP11 acts as a protective deubiquitinase in pathological cardiac hypertrophy by stabilizing SIRT6 and inhibiting the SIRT6-regulated IGF2-AKT signaling axis. Targeting the USP11-SIRT6 pathway may represents a potential therapeutic target for preventing maladaptive cardiac remodeling and heart failure.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s00018-026-06292-0.Keywords: USP11, SIRT6, Cardiac hypertrophy, Deubiquitination, IGF2-AKT signaling, Heart failure Introduction Heart failure, as one possible terminal stage of various cardiovascular diseases, has become a major burden in global public health. It is characterized by sustained loss of myocardial contractile function and aberrant ventricular remodeling [1]. Pathological cardiac hypertrophy serves as a common pathological mechanism during the progression of heart failure. Initially, it serves as a compensatory response to pathological stimuli, such as pressure overload or neurohumoral activation [2], and is characterized by cardiomyocyte hypertrophy and fetal gene re-expression [3]. However, persistent hypertrophy often leads to maladaptive remodeling, myocardial fibrosis, and cardiac dysfunction, ultimately promoting the progression of heart failure [4]. Current therapeutic strategies mainly focus on symptom control and delaying disease progression [5], however, preventing the onset of pathological hypertrophy or interrupting its transition to heart failure remains a major challenge. Achieving early intervention in pathological cardiac hypertrophy and preventing its progression to heart failure requires a clear understanding of the core molecular mechanisms driving this transition [6], particularly the upstream mechanisms regulating the stability of key regulatory proteins [7]. The progression of cardiac hypertrophy is jointly driven by multiple signaling pathways, such as MAPK [8], calcineurin-NFAT [9], and PI3K-AKT [10], relying on the precise regulation of post-translational modification mechanisms. Among these regulatory mechanisms, ubiquitination is a critical reversible post-translational modification that directly influences protein stability and function, thereby modulating signaling pathways and ultimately regulating the cardiac hypertrophic response [11]. Among numerous post-translational modifications, the ubiquitin-proteasome system directly mediates the regulation of protein stability. This reversible process is finely regulated by the deubiquitinating enzyme (DUB) family [12], which comprising nearly a hundred members, with the ubiquitin-specific protease (USP) family being its primary category [13]. Recent studies have revealed that multiple USP proteins are associated with cardiac hypertrophy: USP25 alleviates cardiac hypertrophy by stabilizing SERCA2a protein [14], whereas USP38 exacerbates pathological cardiac hypertrophy by stabilizing TBK1 protein [15]. USP11, as a member of this family, is known to participate in DNA repair, cell apoptosis, and cancer regulation [16–18]. It exerts deubiquitinating activity through a conserved catalytic domain [19], and its substrates include proteins such as SIRT3, PRDX2, and NRF2 [20–22]. However, the biological function and substrates in the heart remain unexplored [23]. Sirtuin 6 (SIRT6), a nuclear NAD⁺-dependent deacetylase with ADP-ribosyltransferase activity, has been established as a key negative regulator of cardiac hypertrophy, metabolism, and aging [24–26]. Previous studies have demonstrated that SIRT6 modulates the mTOR signaling pathway via the transcription factor Sp1, thereby protecting cardiomyocytes from agonist-induced hypertrophy [27]. A previous study suggested that SIRT6 inhibits the IGF-AKT signaling pathway by directly binding to and deacetylating c-Jun [28]. Furthermore, SIRT6 has been shown to protect the heart against aging-related cardiomyocyte dysfunction [29], whereas its deficiency leads to telomere dysfunction, mitochondrial defects, and DNA damage accumulation [30]. Given its multifaceted cardioprotective roles and the characteristic significant fluctuations in its protein levels under stress conditions, the mechanisms regulating SIRT6 protein stability are of considerable interest. The discovery that USP10 stabilizes SIRT6 in cardiomyocytes suggests a potential regulatory mechanism [31, 32]. USP11, a deubiquitinating enzyme with distinct substrates and functions in other biological systems [20], has not been well characterized in heart. However, based on the diversity of the USP family, we hypothesize that different USPs may regulate SIRT6 stability under specific stress conditions, thereby contributing to signaling specificity [33]. Based on the aforementioned observations, we hypothesize that pressure overload-induced downregulation of USP11 decreases SIRT6 stability, thereby contributing to the development of cardiac hypertrophy. Given the established cardioprotective role of SIRT6 and the increasingly prominent importance of DUBs in cardiac remodeling, elucidating whether USP11 stabilizes SIRT6 through deubiquitination could uncover a previously unrecognized mechanism regulating pathological cardiac hypertrophy. Therefore, this study aims to elucidate the deubiquitination-mediated regulatory axis between USP11 and SIRT6 and to investigate its effects on cardiac hypertrophy, cardiac dysfunction, and heart failure progression using in vivo and in vitro models of pathological cardiac hypertrophy. Methods Animal models All animal experiments were conducted in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of The First Affiliated Hospital of Zhengzhou University. 8–10 weeks old male C57BL/6J mice were purchased from HFK Biotechnology (Beijing, China). Mice were randomly assigned to either the sham or transverse aortic constriction (TAC) group. In the TAC group, transverse aortic constriction was performed to induce pressure overload-induced cardiac hypertrophy. In the sham group, mice underwent an identical surgical procedure without aortic ligation. For cardiomyocyte-specific overexpression of USP11, recombinant adeno-associated virus serotype 9 (AAV9) carrying the USP11 gene under the control of the cardiac troponin T (cTnT) promoter was administered via tail vein injection at a dose of 2 × 10¹¹ viral genomes (vg) per mouse. The control group received the corresponding AAV9 vector lacking the USP11 gene but containing a green fluorescent protein (GFP) tag. All recombinant AAV vectors were prepared by Obio Technology Corp., Ltd (Shanghai). Histological analysis For histological analysis, hearts were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned transversely at 5 μm. Consecutive sections were stained with hematoxylin and eosin (HE) to measure cardiomyocyte cross-sectional area. Collagen deposition was assessed using a picrosirius red (PSR) staining kit. Whole-section HE images were captured with a 4× objective. For quantification, five randomly selected non-overlapping LV myocardial fields were analyzed from each mouse, and the mean value was used as one biological replicate (n = 6 mice per group). Cardiomyocyte cross-sectional area was quantified on HE images captured with a 40× objective, and collagen deposition was quantified on PSR images captured with a 20× objective; fields containing large vessels or prominent perivascular collagen were avoided. Images were analyzed using a quantitative digital image analysis system (Image Pro Plus 6.0). Cell culture Neonatal rat ventricular cardiomyocytes (NRVMs) and cardiac fibroblasts (CFs) were isolated from the hearts of 1 to 3-day-old Sprague-Dawley rats (HFK Biotechnology) via enzymatic digestion. The ventricles were excised, cut into approximately 1 mm³ pieces and were digested repeatedly with 0.125% trypsin at 37 °C until the tissue blocks were completely dissociated. The cell suspension was filtered, centrifuged at 1500 rpm for 10 min, and the cell pellet was collected. After treating with red blood cell lysis buffer for 4 min, the cells were centrifuged again and resuspended in DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin. The suspension was incubated at 37 °C for 1–2 h. CFs, which exhibit stronger adhesion properties, firmly attached to the bottom of the culture dishes, while non-adherent cells, primarily NRVMs, remained in suspension. The supernatant containing the NRVMs was collected, centrifuged at 1500 rpm for 10 min, and the pellet was resuspended in DMEM containing 100 µM BrdU (5-bromo-2’-deoxyuridine) to inhibit fibroblast proliferation, along with 10% FBS, and 1% penicillin-streptomycin for further culture. For CFs, DMEM containing 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin was added for continued culture. Vector and mutant construction Full-length USP11 and SIRT6 coding sequences were amplified by PCR and cloned into the pcDNA3.1(+) vector with N-terminal Flag tag (Flag-USP11) or an N-terminal HA tag (HA-SIRT6) using standard restriction enzyme digestion and ligation techniques. The target genes were inserted into the appropriate site of the vector. After transfection, the resulting plasmids enabled expression of USP11 and SIRT6 proteins tagged with Flag or HA. The catalytically inactive USP11 mutant (C318S) was generated by inverse PCR with mutagenic primers (forward: 5′-CAACACGTCCTTCATGAACTCGGCCCTGCAGTGC-3′; reverse: 5′-CATGAAGGACGTGTTGCCCAGATTGGTGAGGCCA-3′), followed by DpnI digestion, gel purification, assembly with the ClonExpress II One Step Cloning Kit (C112-01, Vazyme), and transformation. The ubiquitin mutants (K6O, K11O, K27O, K29O, K33O, K48O, K63O, and K48R) were existing reagents in our laboratory and were used as previously described [34]. For adenoviral overexpression in NRVMs, the coding sequences of wild-type and mutant USP11 were subcloned into the pAdEasy-1 vector system. All constructs were verified by Sanger sequencing. The resulting plasmids were used for transfection and co-immunoprecipitation assays. Cell gene expression manipulation and hypertrophy induction Adenovirus-mediated USP11 overexpression, silencing, and catalytically inactive mutant constructs were used in NRVMs. The following adenoviruses were employed: Ad-Control (empty vector), Ad-USP11 (USP11 overexpression), Ad-sh USP11 (USP11 knockdown), and Ad-USP11-MUT (catalytically inactive mutant C318S overexpression). NRVMs were infected with the adenoviruses at a multiplicity of infection (MOI) of 50 for 24 h post-seeding. Virus-containing medium was added to the culture dishes and incubated for 4 h, followed by replacement with fresh DMEM containing 10% FBS and 1% penicillin-streptomycin. Cells were then cultured for an additional 24 h. Infection conditions for Ad-USP11-MUT were the same as for USP11 overexpression and knockdown. Subsequently, NRVMs were treated with 50 µM phenylephrine (PE) for 24 h to induce hypertrophy. All experiments were conducted in a 37 °C, 5% CO₂ incubator. Western blotting Cells or homogenized heart tissues were lysed in RIPA buffer containing protease and phosphatase inhibitor cocktails (Roche). The lysis solution was then sonicated on ice at 10% power for 2 min. Next, the lysates were centrifuged at 12,000 g for 15 min at 4 °C, and the supernatant protein concentration was measured using a BCA protein assay kit (Thermo Fisher Scientific). After boiling in 5 × SDS-PAGE loading buffer at 95 °C for 10 min, equal amounts of protein were separated by SDS-PAGE and transferred onto PVDF membranes (Millipore). The membranes were blocked with 5% non-fat milk in TBST and then incubated with the indicated primary antibodies overnight at 4 °C (Antibody details are listed in Supplementary Table 1), followed by incubation with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature. Protein bands were visualized using a ChemiDoc XRS+ imaging system (Bio-Rad) with an enhanced chemiluminescence (ECL) substrate (Bio-Rad). Band densities were quantified using ImageJ software. Immunofluorescence NRVMs grown on glass coverslips were fixed with 4% paraformaldehyde for 15 min, permeabilized with 0.1% Triton X-100 for 10 min, and blocked with 5% bovine serum albumin (BSA) for 1 h at room temperature. Cells were then incubated with an appropriate primary antibody overnight at 4 °C, followed by incubation with a corresponding fluorescently labeled secondary antibody. Nuclei were counterstained with 4′, 6-diamidino-2-phenylindole (DAPI). For cardiac tissue immunofluorescence, mice were injected via the tail vein with saline or AAV-Control. Hearts were collected, fixed in 4% paraformaldehyde, cryoprotected in sucrose, embedded in OCT compound, and cut into frozen sections. Sections were stained with indicated antibodies and counterstained with DAPI. Fluorescence images were captured using a confocal microscope (Zeiss). Immunoprecipitation (IP) and liquid chromatography with tandem mass spectrometry (LC-MS/MS) To identify USP11-associated proteins, immunoprecipitation (IP) was performed using lysates from AC16 human cardiomyocyte-like cells. Two IP samples were subjected to LC–MS/MS analysis: a USP11 immunoprecipitation sample (USP11-IP) and a matched IgG immunoprecipitation control sample (IgG). Immunoprecipitated proteins were lysed in SDT lysis buffer, reduced and alkylated using a TCEP/chloroacetamide (CAA) mixture, and digested with sequencing-grade trypsin by the filter-aided sample preparation (FASP) method at 37 °C for 16–18 h. The resulting tryptic peptides were desalted using C18 StageTip columns, vacuum-dried, and reconstituted in 0.1% formic acid (FA). Peptide separation was performed on an Easy-nLC 1200 system using a 60 min gradient elution and was directly coupled to a Q Exactive HF-X mass spectrometer (Thermo Fisher Scientific) operated in data-dependent acquisition (DDA) mode for tandem mass spectrometry analysis. Raw MS/MS data were processed using MaxQuant software against the UniProt reference proteome database (release 2025_06). The main search parameters were set as follows: trypsin was specified as the protease with a maximum of two missed cleavages; carbamidomethylation of cysteine was set as a fixed modification; oxidation of methionine and protein N-terminal acetylation were set as variable modifications. The false discovery rate (FDR) was controlled at ≤ 1% at the protein, peptide, and site levels. Protein groups identified by MaxQuant were exported for downstream analysis. USP11-IP and IgG control datasets were merged based on protein group identifiers, while gene names were retained for annotation. Missing or zero intensity values were imputed using a pseudo-count equal to one-half of the minimum non-zero intensity observed across the two samples, and log2 fold change was calculated as log2 (Intensity_USP11-IP/Intensity_IgG). Because only one USP11-IP sample and one IgG sample were analyzed, log2FC values were used for candidate ranking and prioritization rather than formal statistical inference. Reverse hits, proteins identified only by site, common contaminants, and obvious non-specific background proteins were excluded before downstream candidate selection. Co-immunoprecipitation (Co-IP) Cells or heart tissues were lysed in ice-cold IP lysis buffer supplemented with protease and phosphatase inhibitor cocktails. After centrifugation at 12,000 × g for 15 min at 4 °C, the supernatants were collected. The target antibody was incubated with G-protein agarose beads (Roche) overnight at 4 °C for coupling, following the manufacturer’s instructions (IgG as a control). Cell lysate was then incubated with the antibody-coupled beads overnight at 4 °C for IP. After extensive washing to remove non-specifically bound proteins, bead-bound protein complexes were eluted by boiling in 5 × SDS-PAGE loading buffer. The immunoprecipitated proteins were then subjected to SDS-PAGE and analyzed by immunoblotting with the indicated antibodies. Quantitative real-time PCR (qRT-PCR) Total RNA from tissues or cells was extracted using TRIzol reagent (Takara) according to the manufacturer’s instructions. cDNA was synthesized using the Hifair® III First Strand cDNA Synthesis Kit (Yeasen). Quantitative PCR was performed using SYBR Green Premix (Yeasen) on a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific). The relative mRNA expression levels were calculated using the 2^−ΔΔCt method and normalized to GAPDH expression. The primer sequences used are provided in Supplementary Table 2. Ubiquitination assay In vivo ubiquitination assays were performed under denaturing conditions. Cells were lysed in buffer containing 1% SDS and boiled for 10 min. The lysates were then diluted 10-fold with RIPA buffer to reduce the SDS concentration and subjected to immunoprecipitation with an anti-SIRT6 antibody. The ubiquitination of SIRT6 was detected by Western blotting using an anti-ubiquitin antibody. Statistical analysis All statistical analyses were performed using GraphPad Prism 9.0 software. Data are presented as mean ± standard deviation (SD). For in vitro experiments, each data point (n) represents a biological replicate (independent experiment). For cellular morphology analyses (e.g., cell surface area), at least 20 cells were randomly measured per condition in each independent experiment, and the mean value from each experiment was used for statistical comparison across biological replicates. For ubiquitination data normalized to a theoretical value of 1, a one-sample t-test against 1 was used. The normality of data distribution was assessed using the Shapiro-Wilk test. Comparisons between two groups were analyzed by an unpaired two-tailed Student’s t-test. Comparisons among multiple groups were performed by one-way analysis of variance (ANOVA) followed by Tukey’s post hoc test when the data met the assumptions of normality and homogeneity of variance. For data that satisfied normality but not homogeneity of variance, the Brown-Forsythe ANOVA test coupled with Dunnett’s T3 multiple comparisons test was applied. When the normality assumption was violated, the Kruskal-Wallis (K-W) test was used instead. Results USP11 is downregulated in cardiac hypertrophy USP11 expression was examined in a mouse model of TAC-induced cardiac hypertrophy. Compared with sham groups, TAC markedly decreased USP11 protein and mRNA levels, while increasing BNP protein and mRNA expression (Fig. 1A, B). Echocardiographic analysis was performed at 4 weeks. The results showed that cardiac function was significantly decreased in the TAC group, as evidenced by reduced ejection fraction (EF) and fractional shortening (FS), as well as increased LVEDd, LVESd, and LVPWd. Consistently, anatomical analysis revealed significant increases in HW, HW/BW, LW/BW, and HW/TL, whereas heart rate (HR) was unchanged between groups (Fig. 1C, D). Next, we evaluated USP11 expression in NRVMs and CFs under PE-induced hypertrophic conditions. The results revealed that PE treatment decreased USP11 expression and increased BNP expression in NRVMs, while USP11 expression remained unchanged in CFs (Fig. 1E, F). These results suggest that USP11 is downregulated during cardiac hypertrophy and that this change occurs predominantly in cardiomyocytes. USP11 is downregulated in pathological hypertrophy (A), Western blot of USP11 and BNP in sham vs. TAC (n = 6). (B), qPCR of Usp11 and Nppb in hearts (n = 6). (C), Echocardiographic parameters after 4 weeks of sham or TAC surgery: LVEDd, LVESd, LVPWd, EF, and FS (n = 6). (D), Terminal anatomical and physiological indices: heart weight, HW/BW, LW/BW, HW/TL, and HR (n = 6). (E), Western blot of USP11 and BNP in NRVMs (n = 6). (F), Western blot of USP11 and BNP in CFs (n = 6). LVEDd, Left Ventricular End-Diastolic Dimension; LVESd, Left Ventricular End-Systolic Dimension; LVPWd, Left Ventricular Posterior Wall Dimension at end-diastole; EF, Ejection Fraction; FS, Fractional Shortening; HW, Heart Weight; HW/BW, Heart Weight to Body Weight Ratio; LW/BW, Lung Weight to Body Weight Ratio; HW/TL, Heart Weight to Tibia Length Ratio Cardiomyocyte-specific USP11 overexpression protects against TAC-induced hypertrophy To investigate the role of USP11 in vivo, we used an AAV9-cTnT–based approach to achieve cardiomyocyte-specific overexpression of USP11 (Fig. 2A). Mice underwent TAC surgery 2 weeks after AAV injection. Immunofluorescence confirmed that AAV-Control predominantly targeted cardiomyocytes, and AAV-Control itself did not alter USP11, SIRT6, or IGF2–IGF1R–AKT signaling (Fig. S1). In addition, Doppler assessment of blood flow velocity at the TAC ligation site showed comparable constriction severity between the AAV-Control and AAV-USP11 groups (Fig. S2). Echocardiographic analysis was performed 4 weeks after TAC, and the results showed that USP11 overexpression significantly improved cardiac function, as evidenced by higher EF and FS and reduced LVEDd, LVESd, and LVPWd compared with AAV-Control group (Fig. 2B). Dissection analysis revealed significantly decreased HW, HW/BW, LW/BW, and HW/TL in AAV-USP11 TAC group. However, no significant differences in HR were observed between the groups (Fig. 2C). Histological examination showed significant myocardial hypertrophy and fibrosis in AAV-Control TAC group, with increased cross-sectional area and collagen deposition. However, USP11 overexpression alleviated cardiomyocyte hypertrophy and interstitial fibrosis (Fig. 2D, E). Moreover, mRNA levels of hypertrophic markers (Nppa, Nppb, Myh7) and fibrotic markers (Col1a1, Col3a1, Ctgf) were markedly decreased in AAV-USP11 TAC hearts (Fig. 2F-G). Cardiomyocyte-specific USP11 overexpression mitigates pressure overload-induced hypertrophy, fibrosis, and dysfunction (A) , Western blot of hearts after tail vein injection of AAV-USP11 (n = 6). (B), Representative M-mode echocardiograms and quantified echocardiographic parameters in the indicated groups after 4 weeks of sham or TAC surgery: LVEDd, LVESd, LVPWd, EF, and FS (n = 10). (C), Terminal anatomical and physiological indices: heart weight, HW/BW, LW/BW, HW/TL, and HR (n = 10). (D), Representative cardiac sections of HE and PSR staining (n = 6). Scale bars, 0.5 mm (top), 20 μm (middle), and 50 μm (bottom). (E), Quantification of interstitial collagen area (%) in PSR-stained LV myocardial sections (n = 6), calculated as collagen-positive area divided by total × 100. (F-G), qPCR of Nppa, Nppb, Myh, Col1a1, Col3a1, Ctgf in hearts, (n = 6) USP11 suppresses cardiomyocyte hypertrophy in vitro To explore the functional role of USP11 in vitro, NRVMs were subjected to adenovirus-mediated USP11 overexpression or knockdown (Fig. 3A, D). Overexpression of USP11 significantly suppressed PE-induced increases in cell surface area and hypertrophic marker expression (Nppa, Nppb, Myh7) (Fig. 3B-C). Conversely, USP11 knockdown aggravated PE-induced cardiomyocyte enlargement and upregulation of hypertrophic genes (Nppa, Nppb, Myh7) (Fig. 3E-F). USP11 restrains PE-induced cardiomyocyte hypertrophy in vitro (A), Western blot of USP11 in NRVMs infected with Ad-USP11 or Ad-Control (n = 6). (B), Representative immunofluorescence staining images of cTnT in NRVMs (n = 6). Scale bar, 50 μm. (C), Relative mRNA levels of Nppa, Nppb, Myh7 in NRVMs (n = 6). (D), Western blot showing efficient USP11 knockdown in NRVMs infected with Ad-sh USP11 compared with Ad-sh Scramble (n = 6). (E), Representative immunofluorescence staining images of cTnT in NRVMs (n = 6). Scale bar, 50 μm. F, Relative mRNA levels of Nppa, Nppb, and Myh7 in NRVMs with USP11 knockdown (n = 6) USP11 interacts with and stabilizes SIRT6 To identify potential USP11-interacting or target proteins, we performed immunoprecipitation followed by LC–MS/MS analysis in AC16 human cardiomyocyte-like cells using an anti-USP11 antibody, with matched IgG immunoprecipitation as a control. Proteomic comparison between USP11-IP and IgG samples revealed that SIRT6 was among the top enriched non-background proteins in USP11 immunoprecipitates (Fig. 4A). The annotated MS/MS spectrum of SIRT6 is shown in Fig. S3, and the complete LC–MS/MS results are provided in Supplementary Table 3. Exogenous co-IP in 293 T cells and endogenous co-IP in cardiomyocytes further confirmed the interaction between USP11 and SIRT6 (Fig. 4B, C). To explore the downstream mechanism, the protein levels of SIRT6, p-IGF1R, IGF2, p-AKT, and AKT were examined in NRVMs with USP11 overexpression or knockdown under PE stimulation. The results showed that USP11 overexpression increased SIRT6 protein levels and attenuated PE-induced increases in p-IGF1R, IGF2, and p-AKT (Fig. 4D). Similar results were obtained in vivo (Fig. S4A). In contrast, USP11 knockdown produced the opposite effect (Fig. 4E). USP11 interacts with and stabilizes SIRT6 (A), Mass spectrometry of anti-USP11 IP identifies SIRT6 among the top USP11-associated proteins. (B), Co-IP of exogenous Flag-USP11 and HA-SIRT6 confirms the interaction. (C), Endogenous IP with anti-USP11 or anti-SIRT6 confirms the interaction; IgG serves as a negative control. (D), Western blot of the indicated proteins in NRVMs infected with Ad-USP11 (n = 6). (E), Western blot of the indicated proteins in NRVMs infected with Ad-sh USP11 (n = 6) USP11 deubiquitinates SIRT6 and prevents its proteasomal degradation To explore the mechanism underlying SIRT6 upregulation following USP11 overexpression, we first performed a CHX chase assay to determine the half-life of SIRT6. The results showed that Ad-USP11 prolonged the half-life of SIRT6, whereas the catalytic mutant USP11 (C318S) (Ad-USP11-MUT) failed to do so (Fig. 5A). To further clarify the mechanism by which USP11 regulates SIRT6 stability, MG132 and chloroquine (CQ) were treated after USP11 knockdown. The results showed MG132, but not CQ, restored the reduction in SIRT6 protein levels caused by USP11 silencing, indicating that USP11 preserves SIRT6 stability through proteasomal rather than lysosomal degradation (Fig. 5B). Then the ubiquitination level of SIRT6 was examined. In TAC hearts, SIRT6 ubiquitination levels were elevated compared with sham group (Fig. 5C). In vivo ubiquitination assays following USP11 overexpression showed that USP11 reduced the ubiquitination level of SIRT6 (Fig. S4B). In vitro ubiquitination assays further revealed that USP11 reduces SIRT6 ubiquitination (Fig. 5D). Mutation analyses demonstrated that USP11 specifically removes K48-linked ubiquitin chains from SIRT6 (Fig. 5E-F). These findings indicate that USP11 stabilizes SIRT6 by removing K48-linked ubiquitin chains, thereby preventing its proteasomal degradation. USP11 inhibits the ubiquitin-mediated degradation of SIRT6 by deubiquitination (A), CHX chase assay in NRVMs infected with Ad-USP11 or Ad-USP11-MUT (n = 6), (*, Ad-Control vs. Ad-USP11, P < 0.01; #, Ad-USP11 vs. Ad-USP11-MUT, P < 0.01). (B), Western blot of SIRT6 and USP11 in NRVMs infected with Ad-sh USP11 after treated with MG132 or CQ (n = 6). (C), The ubiquitination level of SIRT6 after TAC (n = 6). (D), Co-expression of Flag-USP11 reduced ubiquitinated HA-SIRT6 in cells (n = 6). (E), Ubiquitin-linkage screen with lysine-only Ub mutants (K6, K11, K27, K29, K33, K48, and K63) (n = 6). (F), Validation with WT, K48O and K48R Ub showed that USP11 reduced SIRT6 ubiquitination with WT and K48O, but not K48R (n = 6) SIRT6 mediates the protective effects of USP11 To determine whether SIRT6 is required for USP11 to alleviate myocardial hypertrophy, we conducted rescue experiments. Overexpression of catalytic mutant USP11 (C318S) failed to suppress PE-induced hypertrophy and the activation of IGF2-AKT signaling and the increase in hypertrophy marker expression (Nppa, Nppb, Myh7) did not improve (Fig. 6A-C). However, re-expression of SIRT6 in USP11-knockdown cells reversed the enhanced hypertrophic response and inhibited the activation of IGF2-AKT signaling, resulting in suppressed expression of hypertrophy markers (Nppa, Nppb, Myh7) (Fig. 6D-F). Conversely, knockdown of SIRT6 in USP11-overexpressing cells abolished the inhibitory effect of USP11 on cardiomyocyte hypertrophy. It also abolished the inhibitory effect of USP11 on IGF2-AKT signaling activation (Fig. S5A-C). These data indicate that USP11 exerts its anti-hypertrophic effects primarily through stabilization of SIRT6 and subsequent inhibition of the activation of IGF2-AKT axis. SIRT6 mediates the protective effects of USP11 (A), Representative immunofluorescence staining images of cTnT in NRVMs infected with Ad-USP11-MUT (n = 6). Scale bar, 50 μm. (B), Western blot of p-IGF1R, IGF2, p-AKT, AKT, SIRT6 and USP11 in NRVMs infected with Ad-USP11-MUT (n = 6). (C), qPCR of Nppa, Nppb, Myh7 in NRVMs infected with Ad-USP11-MUT (n = 6). (D), Representative immunofluorescence staining images of cTnT in NRVMs infected with Ad-sh USP11 and Ad-SIRT6 (n = 6). Scale bar, 50 μm. E, Western blot of p-IGF1R, IGF2, p-AKT, AKT, SIRT6 and USP11 in NRVMs infected with Ad-sh USP11 and Ad-SIRT6 (n = 6). F, qPCR analysis of Nppa, Nppb, Myh7 in NRVMs infected with Ad-sh USP11 and Ad-SIRT6 (n = 6) Discussion Pathological cardiac hypertrophy represents a critical adaptive response of the organism to hemodynamic stress, often progressing to maladaptive remodeling and heart failure [4]. Although substantial advances have been achieved in elucidating the molecular mechanisms underlying cardiac hypertrophy, the regulatory roles of DUBs remain incompletely understood. This study systematically unveils the negative regulatory mechanism of the USP11-SIRT6 axis in pathological cardiac hypertrophy. We demonstrate that USP11 stabilizes SIRT6 via deubiquitination, thereby suppressing the IGF2-AKT pro-hypertrophic signaling pathway. The core findings are elaborated from four perspectives: expression patterns, functional validation, molecular basis, and clinical translation. USP11 is downregulated in pathological cardiac hypertrophy, and its function is associated with anti-hypertrophic effects. In TAC-induced mouse cardiac hypertrophy models and PE-stimulated primary cardiomyocyte hypertrophy models, the expression of USP11 is markedly reduced, indicating that its deficiency may represent a common feature of pathological remodeling. However, USP11 expression remained unchanged in fibroblasts, suggesting that its role in this process is mainly exerted in cardiomyocytes. Functional validation demonstrates that cardiomyocyte-specific overexpression of USP11 significantly attenuates pressure overload-induced cardiac hypertrophy, improves cardiac function, and reduces fibrosis, whereas USP11 deficiency exacerbated these changes, highlighting a protective role for USP11 in pathological cardiac remodeling. Mechanistic studies reveal that USP11 exerts potential anti-hypertrophic effects through direct binding and deubiquitination of SIRT6. Using IP combined with LC-MS/MS, we confirmed SIRT6 as a substrate of USP11. USP11 specifically removes K48-linked ubiquitin chains from SIRT6, thereby inhibiting its proteasomal degradation and extending its protein half-life. Notably, catalytically inactive USP11 mutants completely abolish the protective effect, demonstrating that this function strictly depends on USP11’s deubiquitinating enzyme activity. Further studies demonstrated that USP11 suppresses activation of the IGF2–AKT pathway by stabilizing SIRT6 through deubiquitination. In vitro rescue experiments, SIRT6 restoration completely reversed the hypertrophy induced by USP11 deficiency, confirming that SIRT6 is a key downstream mediator of USP11. Although in vivo causal validation via AAV-SIRT6 overexpression or knockout models has not yet been performed, we systematically compared our USP11-overexpressing mouse model with previously reported SIRT6 study [28], further supporting the notion that USP11 attenuates pathological hypertrophy by stabilizing SIRT6 and inhibiting IGF2-AKT signaling. Specifically, in TAC-treated non-transgenic mice, cardiac hypertrophy was evident by increased HW/TL, increased LVPWd, reduced FS, enlarged cardiomyocyte cross-sectional area, and enhanced fibrosis. In contrast, cardiomyocyte-specific SIRT6 transgenic mice did not exhibit similar pathological changes following TAC [28]. These observations are highly consistent with our findings that USP11 overexpression mitigates cardiac hypertrophy and dysfunction by stabilizing SIRT6 and suppressing IGF2-AKT signaling. Collectively, these data suggest that both USP11 overexpression and SIRT6 overexpression can prevent the development of pathological cardiac hypertrophy. Unlike USP28 and USP14, which promote cardiac hypertrophy by deubiquitinating pro-hypertrophic factor [35, 36], USP11 represents a distinct class of cardioprotective DUBs that suppress pressure overload-induced pathological cardiac remodeling by enhancing the stability of negative regulators of pathological growth, such as SIRT6. Although the cardioprotective role of SIRT6 has been well documented in numerous studies, our research proposes the potential role of USP11 as an upstream regulator of SIRT6. Through a deubiquitination mechanism, USP11 stabilizes SIRT6, thereby counteracting pathological processes such as cardiac hypertrophy and fibrosis. This study offers a new perspective on the potential application of USP11 in heart disease. Our findings showed that cardiomyocyte-specific overexpression of USP11 reduces hypertrophy and fibrosis. However, in the absence of in vivo USP11 knockout or knockdown experiments, these results only suggest a potential cardioprotective role for USP11 rather than providing definitive evidence. Restoration of USP11 expression may therefore represent a potential protective strategy. In future studies, we will conduct knockout and expression restoration experiments to further validate the role of USP11 in pathological cardiac remodeling and explore its translational potential in clinical therapy. In addition, several issues still require further investigation. The upstream regulatory network of USP11 in the heart, including transcriptional and post-translational regulation, remains to be elucidated. Its roles in other cardiovascular cell types, such as fibroblasts and endothelial cells, also await cell-specific investigations. Furthermore, the crosstalk between USP11 and other DUBs or acetylases require further exploration, as different regulatory proteins may differentially modulate SIRT6 activity under physiological or pathological conditions. Despite these limitations, our study establishes the central position of the USP11-SIRT6 axis. In summary, our study demonstrates that USP11 functions as a novel regulator of pathological cardiac hypertrophy by stabilizing SIRT6 and thereby suppressing activation of the IGF2-AKT signaling pathway. The USP11-SIRT6 axis may play an important role in maintaining cardiac homeostasis and represents a potential therapeutic target for pathological cardiac remodeling and heart failure. Collectively, these findings deepen our understanding of protein stability regulation in cardiovascular biology and offer new perspectives for the treatment of cardiac diseases. Conclusion USP11 functions as a potential protective deubiquitinase in pathological cardiac hypertrophy by stabilizing SIRT6 and suppressing IGF2-AKT signaling. Targeting the USP11-SIRT6 axis may provide a potential therapeutic strategy for treating maladaptive cardiac remodeling and heart failure. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 (XLSX 21.2 KB) Supplementary Material 2 (DOCX 943 KB) Author contributions XW, WZ and DZ spearheaded and planned this study and performed the experiments. XJ, XA, ZL, LK, YW, YF, LG and YL oversaw the execution of the experiments and interrogated the data. GL, ZZ and SF wrote the manuscript. All authors reviewed and sanctioned the final version of the manuscript. Funding This work was supported by the Natural Science Foundation of Henan Province (Grant No. 252300423867) and the Medical Science and Technology Research Project of Henan Province (Grant No. LHGJ20220286). Data availability The mass spectrometry data generated in this study are provided in Supplementary Table 3. Other data supporting the findings of this study are available from the corresponding author upon reasonable request. Declarations Conflict of interest The authors declare no conflicts of interest. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xijia Wang, Wenzhe Zong and Di Zhou contributed equally as first authors. Contributor Information Zhe Zheng, Email: zhengzhezhengzhou@163.com. Gangqiong Liu, Email: doctorliu61352@163.com. Siyuan Fan, Email: 985645270@qq.com. References Associated Data Data Availability Statement The mass spectrometry data generated in this study are provided in Supplementary Table 3. Other data supporting the findings of this study are available from the corresponding author upon reasonable request.